Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Welcome to Attea Pharmaceuticals' first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If you should require operator assistance during the conference, please press star zero on your telephone keypad. I will now turn it over to the Attea management team. Please go ahead. Hi, thank you, Operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals' first quarter 2026 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by visiting the investor section of our website at ir.ateafarma.com. With me today from Atea are our Chief Executive Officer and Founder, Dr. Jean-Pierre Samadosi, Chief Development Officer, Dr. Janet Hammond, Chief Commercial Officer, John Vavrica, Chief Medical Officer, Dr. Arantahorga, and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, who will all be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risk and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre. Thank you, Joné. Good afternoon, everyone, and thank you for joining us. I will be...